Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R. Pavone-Macaluso M, et al. Among authors: de voogt hj, de pauw m. J Urol. 1986 Sep;136(3):624-31. doi: 10.1016/s0022-5347(17)44996-2. J Urol. 1986. PMID: 2942707 Clinical Trial.
Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762.
de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S. de Voogt HJ, et al. Among authors: de pauw m. J Urol. 1986 Feb;135(2):303-7. doi: 10.1016/s0022-5347(17)45620-5. J Urol. 1986. PMID: 2935644 Clinical Trial.
A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
Smith PH, Suciu S, Robinson MR, Richards B, Bastable JR, Glashan RW, Bouffioux C, Lardennois B, Williams RE, de Pauw M, et al. Smith PH, et al. Among authors: de pauw m. J Urol. 1986 Sep;136(3):619-23. doi: 10.1016/s0022-5347(17)44995-0. J Urol. 1986. PMID: 3525866 Clinical Trial.
Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).
Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R. Newling DW, et al. Among authors: de pauw m. J Urol. 1993 Dec;150(6):1840-4. doi: 10.1016/s0022-5347(17)35911-6. J Urol. 1993. PMID: 8230517 Clinical Trial.
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
de Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R. de Voogt HJ, et al. Among authors: de pauw m. Eur Urol. 1998;33(2):152-8. doi: 10.1159/000019547. Eur Urol. 1998. PMID: 9519356 Clinical Trial.
Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group.
Bouffioux C, Denis L, Oosterlinck W, Viggiano G, Vergison B, Keuppens F, De Pauw M, Sylvester R, Cheuvart B. Bouffioux C, et al. Among authors: de pauw m. J Urol. 1992 Aug;148(2 Pt 1):297-301. doi: 10.1016/s0022-5347(17)36577-1. J Urol. 1992. PMID: 1635122 Clinical Trial.
Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.
de Voogt HJ, Klijn JG, Studer U, Schröder F, Sylvester R, De Pauw M. de Voogt HJ, et al. Among authors: de pauw m. J Steroid Biochem Mol Biol. 1990 Dec 20;37(6):965-9. doi: 10.1016/0960-0760(90)90451-p. J Steroid Biochem Mol Biol. 1990. PMID: 2149509 Clinical Trial.
EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group.
Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, de Pauw M, Sylvester R, Smith PH, Suciu S. Pavone-Macaluso M, et al. Among authors: de voogt hj, de pauw m. Prog Clin Biol Res. 1989;303:111-6. Prog Clin Biol Res. 1989. PMID: 2528735 Clinical Trial. No abstract available.
257 results